Why the study?
Is measurement of TPV superior to IMT and TPA for assessing response to antiatherosclerotic therapy?
Is measurement of TPV superior to IMT and TPA for assessing response to antiatherosclerotic therapy?
Measurement of carotid total plaque volume is a superior imaging biomarker compared to intima-media thickness and total plaque area for assessing response to antiatherosclerotic therapy.
TPV may better track antiatherosclerotic therapy response than IMT or TPA; leaves open need for outcome validation before adoption.
For assessment of response to antiatherosclerotic therapy, measurement of TPV is superior to both IMT and TPA.
No takes yet. Share an insight, caveat, or question.
Wannarong et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: